Here we report vaccination outcomes in a small cohort of solid CPs including a cohort of long survivors under immunotherapy (cohort B, subgroup B.1) with checkpoint inhibitors (mainly anti PD-1/PD-L1 antibodies) and relate them to COVID-19 vaccine studies of cancer patients that have been published until January 2022 (3, 14, 16, 18–28). Here, CD274 is linked to cancer.